5 research outputs found
Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model
IntroductionPost-acute sequelae of COVID-19 seem to be an emerging global crisis. Machine learning radiographic models have great potential for meticulous evaluation of post-COVID-19 interstitial lung disease (ILD).MethodsIn this multicenter, retrospective study, we included consecutive patients that had been evaluated 3 months following severe acute respiratory syndrome coronavirus 2 infection between 01/02/2021 and 12/5/2022. High-resolution computed tomography was evaluated through Imbio Lung Texture Analysis 2.1.ResultsTwo hundred thirty-two (n = 232) patients were analyzed. FVC% predicted was ≥80, between 60 and 79 and <60 in 74.2% (n = 172), 21.1% (n = 49), and 4.7% (n = 11) of the cohort, respectively. DLCO% predicted was ≥80, between 60 and 79 and <60 in 69.4% (n = 161), 15.5% (n = 36), and 15.1% (n = 35), respectively. Extent of ground glass opacities was ≥30% in 4.3% of patients (n = 10), between 5 and 29% in 48.7% of patients (n = 113) and <5% in 47.0% of patients (n = 109). The extent of reticulation was ≥30%, 5–29% and <5% in 1.3% (n = 3), 24.1% (n = 56), and 74.6% (n = 173) of the cohort, respectively. Patients (n = 13, 5.6%) with fibrotic lung disease and persistent functional impairment at the 6-month follow-up received antifibrotics and presented with an absolute change of +10.3 (p = 0.01) and +14.6 (p = 0.01) in FVC% predicted at 3 and 6 months after the initiation of antifibrotic.ConclusionPost-COVID-19-ILD represents an emerging entity. A substantial minority of patients presents with fibrotic lung disease and might experience benefit from antifibrotic initiation at the time point that fibrotic-like changes are “immature.” Machine learning radiographic models could be of major significance for accurate radiographic evaluation and subsequently for the guidance of therapeutic approaches
Respiratory Symptoms and Pulmonary Function of Workers in the Waste Management Industry
Introduction: Waste handling workers are exposed to air pollutants and
toxic compounds produced during waste management and processing that can
cause respiratory symptoms and lung function impairment. This study
aimed to evaluate the respiratory health of exposed workers in a waste
management plant in Attica, Greece.
Methods: 50 field workers exposed to outdoor pollutants (exposure group)
and 32 office clerks with no exposure (control group) were evaluated.
Upper and lower respiratory symptoms were documented and spirometry was
performed.
Results: There was no statistically significant difference between the
exposure and the control group in forced expiratory volume in one second
(FEV1)%, forced vital capacity (FVC)%, FEV1/FVC% predicted values.
Workers had lower maximal mid-expiratory flow (MMEF)% predicted values
compared to controls (82% vs 94%, p=0.019). No difference was observed
regarding the respiratory symptoms between the two groups.
Conclusion: Lower MMEF values were observed in the exposure group. Low
MMEF can be indicative of small airway disease, thus smoking cessation,
close follow-up, and the use of personal protective equipment are
recommended
Pulmonary adverse events due to immune checkpoint inhibitors: A literature review.
Cancer immunotherapy aims to stimulate the immune system to fight against tumors, utilizing the presentation of molecules on the surface of the malignant cells that can be recognized by the antibodies of the immune system. Immune checkpoint inhibitors, a type of cancer immunotherapy, are broadly used in different types of cancer, improving patients' survival and quality of life. However, treatment with these agents causes immune-related toxicities affecting many organs. The most frequent pulmonary adverse event is pneumonitis representing a non-infective inflammation localized to the interstitium and alveoli. Other lung toxicities include airway disease, pulmonary vasculitis, sarcoid-like reactions, infections, pleural effusions, pulmonary nodules, diaphragm myositis and allergic bronchopulmonary aspergillosis. This review aims to summarize these pulmonary adverse events, underlining the significance of an optimal expeditious diagnosis and management